Roche Venture Fund was among the existing investors that helped supply $50m for Arch Oncology, the cancer drug developer formerly known as Tioma.

The CNPG-backed oncology therapy developer boosted its overall funding to $70m in a round backed by Eli Lilly and CICC Capital.

The employee management platform developer has completed an M12-led round that took its overall funding past the $40m mark and will use the cash for hiring.

Amgen Ventures, MRL Ventures Fund and Pharmaron contributed to a round that almost doubled the total raised by the bone marrow disease drug developer since 2012.

Workday joined existing investor Microsoft in a round that will support the development of WorkBoard's enterprise planning software, taking its total funding to $35m.

The data centre technology developer will put the proceeds from the CUI-led round into its marketing and research and development activities.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Based on Stanford research, Surrozen is working on regenerative treatments for a wide range of conditions, with a first focus on liver disease.

Home equity investment service Point has raised $22m in series B funding from investors including Prudential and Bloomberg, and $100m in platform financing.

The JD.com-backed office equipment leasing service has increased its overall funding to nearly $60m in a $22.3m pre-series B round.